Lexaria Bioscience Corp. (LEXX) income statement
LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày May 31, 2026Last filing: 10-Q on Jul 13, 2026Score 8/30
$4.28+0.10 (+2.39%)
Close on Nov 18, 2026Market cap $106.09MP/E –Yield –
Lexaria Bioscience Corp. income statement
Ratios
Latest available, balances at May 31, 2026
Profitability, TTM
- Gross margin
- 100.0%
- Operating margin
- -3973.2%
- Net margin
- -3985.6%
- Return on equity, FY2025
- -215.9%
Financial strength
- Current ratio
- 10.60
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 912.9%
Valuation
- P/E ratio
- –
- Price to sales
- 546.86
- Price to book
- 22.39
- Dividend yield
- –
See a number that looks wrong?